Myeloproliferative Disorder Presenting As Portal And Mesenteric Venous Thrombosis - A Case Report
Main Article Content
Abstract
Myeloproliferative disorders (MPD) can present as unprovoked venous thrombosis, in particular abdominal venous thrombosis. The events of thrombosis can occur even in the presence of a normal peripheral cell counts. We report the case of a 32 year old male presenting with abdominal pain, sitophobia and non-tender splenomegaly. Investigations done revealed high platelet counts, gastroscopy showed large oesophageal varices, portal doppler showed normal liver echoes and cavernous transformation of portal vein, CECT abdomen showed chronic portal and superior mesenteric venous thrombosis. Bone marrow biopsy revealed increased megakaryocytic precursors and JAK2V617F mutation was positive. Hence a diagnosis of myeloproliferative disorder (essential thrombocythemia ) presenting as portal and mesenteric venous thrombosis was made. Patient underwent endoscopic variceal ligation followed by anticoagulation and Hydroxyurea therapy. He showed good response to treatment till date. This case highlights the importance of thorough screening for myeloproliferative disorders in patients presenting with portal and mesenteric vein thrombosis.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
Michiels JJ, Berneman Z, Schroyens W, HebedaK, LamK, De Raeve H.The 2001 WHO and updated European clinical and pathological criteria for the diagnosis, classification and staging of Philadelphia chromosome-negative chronic myeloproliferative disorders. Semin Thrombin Hemost2006 Jun;32(4 Pt 2):307-40
Tefferi A, Pardanani A. Mutation screening for JAK2V617F: when to order the test and how to interpret the results. Leukemia 2006; Res 108:3472–3476
Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275–290
Johnson M, Gernsheimer T, Johansen K. Essential thrombocytosis: underemphasized cause of large-vessel thrombosis. J Vasc Surg 1995; 22:443–449.
Kessler CM, Cline HG, Havlik RJ. Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br J Hematol 1982;50:157-60
Randi ML, Stocco F, Rossi C, Tison T, Girolami A. Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases). J Med 1991; 22:213-223.
Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH, Portal vein thrombosis: Prevalence, patient characteristics and lifetime risk: A population study based on 23 796 consecutive autopsies. World J Gastroenterol. Apr 7, 2006; 12(13): 2115-2119
Kiladjian JJ, Cervantes F, Leebeek FWG, Marzac C, Chevret S, Cassinat B,et al. Role of JAK 2 mutation detection in Budd-Chiari syndrome (BCS) and portal vein thrombosis (PVT) associated to MPD. Blood,2006;108:116a
Malkowski P, Pawlak J, Michalowicz B, Szczerban J,Wroblewski T,Leowska E,et al, Thrombolytic treatment of portal thrombosis.Hepatogastroenterology, 2003;50:2098